Perspective Therapeutics, Inc. (CATX) Financial Statements
Free cash flow over the same period: -$121.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CATXPerspective Therapeutics, Inc.Follow CATX — free
—
Price chart with a free account
- Market cap
- 183.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2012 Jun 12 | FY2013 Jun 13 | FY2014 Jun 14 | FY2015 Jun 15 | FY2016 Jun 16 | FY2017 Jun 17 | FY2018 Jun 18 | FY2019 Jun 19 | FY2020 Jun 20 | FY2021 Jun 21 | FY2022 Jun 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | 0.7 | 0.2 | -0.2 | 0.2 | 0.1 | 0.8 | 1.8 | 3.0 | 5.1 | 5.1 | 0.0 | 1.4 | — | — | — | |
| Research & development | 0.8 | 0.6 | 0.7 | 0.6 | 0.5 | 1.0 | 1.7 | 1.5 | 1.1 | 1.4 | 0.9 | 21.3 | 41.6 | 84.2 | 96.2 | |
| Operating income | -3.6 | -4.1 | -4.6 | -4.3 | -5.1 | -6.3 | -6.7 | -5.3 | -3.5 | -3.4 | -6.4 | -40.9 | -90.9 | -113.6 | -125.2 | |
| Pre-tax income | — | — | -6.0 | -3.7 | -4.7 | -6.2 | -6.7 | -5.1 | — | — | — | -40.1 | -80.4 | -104.4 | -117.4 | |
| Income tax | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.7 | -2.1 | -0.8 | — | |
| Net income | -3.5 | -3.9 | -6.0 | -3.7 | -4.7 | -6.2 | -6.7 | -5.1 | -3.4 | -3.4 | -7.3 | -46.5 | -79.3 | -103.1 | -116.4 | |
| Diluted EPS ($) | -0.12 | -0.11 | -0.16 | -0.07 | -0.09 | -0.11 | -0.12 | -0.08 | -0.05 | -0.03 | — | — | -1.23 | -1.40 | -0.96 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | — | — | — | — | 64.4 | 73.8 | — |
USD millions · SEC XBRL
Perspective Therapeutics, Inc. — questions
- What is Perspective Therapeutics, Inc.'s net income?
- -$116.4M over the twelve months to 2026-06-30.
- What is Perspective Therapeutics, Inc.'s free cash flow?
- -$121.3M over the twelve months to 2026-06-30.
- What are Perspective Therapeutics, Inc.'s diluted earnings per share?
- $-0.96 over the twelve months to 2026-06-30.
Every figure on this page comes from Perspective Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.